A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease
Authors
SangYun Kim (ORCID: https://orcid.org/0000-0002-9101-5704)
Fred Kim (ORCID: https://orcid.org/0000-0001-6010-3544)
Marshall Nash
James Rock
Niels D. Prins (ORCID: https://orcid.org/0000-0002-6297-7592)
Jonathan A. Busam (ORCID: https://orcid.org/0000-0002-1905-5170)
Jai Jun Choung
David Greeley (ORCID: https://orcid.org/0000-0003-2811-3835)
Brad Herskowitz
Sharon J. Sha (ORCID: https://orcid.org/0000-0002-3666-1463)
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease
SangYun Kim, Fred Kim, Marshall Nash, James Rock et al.
Citations
2 citations
Journal
The Journal of Prevention of Alzheimer s Disease
Topics
Phosphodiesterase function and regulation
Field-Weighted Citation Impact (FWCI)
1.61
article
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease
SangYun Kim, Fred Kim, Marshall Nash, James Rock, Niels D. Prins, Jonathan A. Busam, Jai Jun Choung, David Greeley, Brad Herskowitz, Sharon J. Sha, Tianyang Xi, Benoit Tete
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
The Journal of Prevention of Alzheimer s DiseaseVol. 12(9)
Institutions
Dartmouth College (US), Autism Research Institute (US), University of Miami (US), New Generation University College (ET), Stanford Health Care (US), Virtually Better (US), Arthritis Northwest (US)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease — SangYun Kim, Fred Kim, et al. · The Journal of Prevention of Alzheimer s Disease (2025) | TGRS Research Map | TGRS